We report the repeated isolation of *Bordetella petrii* in the sputum of a 79-year-old female patient with diffuse bronchiectasis and persistence of the bacterium for >1 year. The patient was first hospitalized due to dyspnea, which developed into severe cough with purulent sputum that yielded *B. petrii* on culture. After this first episode, the patient was hospitalized an additional 4 times with bronchorrhea symptoms. The isolates collected were analyzed by using biochemical, genotypic, and proteomic tools. Expression of specific proteins was analyzed by using serum samples from the patient. The *B. petrii* isolates were compared with other *B. petrii* isolates collected from humans or the environment and with isolates of *B. pertussis, B. parapertussis, B. bronchiseptica,* and *B. holmesii,* obtained from human respiratory tract infections. Our observations indicate that *B. petrii* can persist in persons with chronic pulmonary obstructive disease as has been previously demonstrated for *B. bronchiseptica.*

The genus *Bordetella* comprises 9 species; all, except *B. petrii,* are obligatorily associated with host organisms (1). The first isolations of *B. anisorpii* were from a cyst (2) and from a blood sample (3), whereas *B. trematum* has been isolated from infected ears and from wounds in humans. The reservoir and the pathogenic role of these 2 species remain unknown (4). *B. pertussis,* a strictly human pathogen, and *B. parapertussis,* a pathogen in both humans and sheep, are agents of whooping cough (5). *B. avium* and *B. hinzii* caused respiratory infections in birds and poultry and have also been reported to cause infections in humans (6–9). The latter 4 *Bordetella* spp. are usually described as extracellular bacteria that secrete adhesins and toxins adapted to their hosts (10).

However, 2 other *Bordetella* species, *B. bronchiseptica* and *B. holmesii,* behave differently and are able to persist inside their hosts. *B. bronchiseptica* is a respiratory pathogen which may cause acute or chronic bronchopneumonia and is found in many animals, including dogs, cats, pigs, and rabbits, as well as humans (11,12). *B. holmesii,* originally described as Centers for Disease Control and Prevention nonoxidizer group 2 (NO-2), has been isolated from the blood cultures of young adults, mostly with underlying disorders or from sputum (13–15). The reservoir of this bacterium is unknown. However, *B. petrii* has also been isolated from patients with cystic fibrosis (16–19). Unlike the “classical” pathogenic species, *B. pertussis* and *B. parapertussis,* *B. petrii,* *B. holmesii,* and *B. bronchiseptica,* have the ability to acquire or exchange genomic regions (20,21). *B. petrii* possesses the largest number of huge genomic islands collectively known as integrative and conjugative elements (22,23). Several determinants of virulence expressed by *B. pertussis,* *B. parapertussis,* and *B. bronchiseptica,* such as filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae (Fim2 and Fim3), and toxins such as pertussis toxin (PT) and adenylate cyclase-hemolysin (AC-Hly) were not detected in *B. petrii,* except for an FHA-related adhesin with low similarity (22). In this study, we describe an immunocompetent adult with predisposing factors (chronic obstructive respiratory disease and local corticotherapy) who acquired an acute *B. petrii* infection that had long-lasting persistence.

**Materials and Methods**

**Case History**

A 79-year-old nonfebrile woman was hospitalized in October 2007 with dyspnea, which had progressed
over 1 week to severe coughing with abundant purulent and hemoptoic sputum, although the patient had been treated with respiratory physiotherapy and corticosteroid aerosols at home (which was in poor hygienic condition). C-reactive protein level was only moderately elevated (27 mg/mL, reference <10 mg/mL). This patient had experienced pulmonary tuberculosis 33 years earlier and had been successfully treated. For 30 years, she had diffuse bronchiectasis, which had required a right middle lobectomy 23 years previously. She had a myocardial infarction 6 years ago. The patient also had severe chronic hyponatremia, diagnosed as Schwartz-Bartter syndrome, which may have been related to a chronic respiratory deficiency. At admission, a purulent sputum sample was taken (class 5 of Bartlett-Murray and Washington criteria) (24) yielded a monomicrobial culture (10⁶ CFU/mL) of B. petrii. After receiving empirical treatment with amoxicillin-clavulanate, the patient improved slowly and was discharged after 2 weeks. Over the next 12 months, the patient returned with bronchorrhea with amoxicillin and clavulanate, the patient improved over 1 week to severe coughing with abundant purulent and hemoptoic sputum, although the patient had been treated with respiratory physiotherapy and corticosteroid aerosols at home (which was in poor hygienic condition). C-reactive protein level was only moderately elevated (27 mg/mL, reference <10 mg/mL). This patient had experienced pulmonary tuberculosis 33 years earlier and had been successfully treated. For 30 years, she had diffuse bronchiectasis, which had required a right middle lobectomy 23 years previously. She had a myocardial infarction 6 years ago. The patient also had severe chronic hyponatremia, diagnosed as Schwartz-Bartter syndrome, which may have been related to a chronic respiratory deficiency. At admission, a purulent sputum sample was taken (class 5 of Bartlett-Murray and Washington criteria) (24) yielded a monomicrobial culture (10⁶ CFU/mL) of B. petrii. After receiving empirical treatment with amoxicillin-clavulanate, the patient improved slowly and was discharged after 2 weeks. Over the next 12 months, the patient returned with bronchorrhea symptoms in November and December 2007 and in May and November 2008. Each time, B. petrii was isolated from purulent sputum specimens in either pure or mixed cultures (in the second sputum culture, B. petrii 10⁶ CFU/mL and Citrobacter freundii 10⁴ CFU/mL; in the third sputum culture, B. petrii 10⁸ CFU/mL and C. freundii 10⁸ CFU/mL; in the fourth culture, B. petrii 10⁷ CFU/mL pure culture; in the fifth culture, B. petrii 10⁵ CFU/mL and Haemophilus parainfluenzae 10⁵ CFU/mL; and in the last sputum culture, B. petrii 10⁶ CFU/mL pure culture). These episodes did not require hospitalization, and the patient’s symptoms were empirically treated with amoxicillin and clavulanate. However, during these repetitive episodes, the patient did not have any general symptoms of sepsis (no fever nor elevated C-reactive protein level). The reactivation of tuberculosis and infection with other mycobacteria were excluded by 3 microscopic examinations and liquid and solid cultures. The patient died in January 2009 from deep electrolytic disorders related to Schwartz-Bartter syndrome.

Bacterial Isolation, Identification, DNA Extraction, and Growth Conditions

Sputum samples (25) were plated onto the following agar plates: chocolate PolyViteX agar for bacterial enumeration, bromo-cresol purple (BCP) agar plates, selective Haemophilus (chocolate bacitracin) agar, Columbia agar with nalidixic acid and 5% sheep blood (all from bioMérieux, Marcy-l’Etoile, France), and CHROMagar Candida (BBL, Becton, Dickinson and Company, Le Pont de Claix, France). Plates were incubated at 37°C for 24 h and for 48 h in a humidified atmosphere with 9% CO₂. For each sample, 10⁵–10⁸ CFU/mL were observed and characterized. At 48 h, small colonies of a gram-negative bacterium were detected on the first 3 media. Routine identification was performed by a Gram-Negative Identification card on a VITEK 2 automate (bioMérieux) and manually by using API 20NE, API 32GN (bioMérieux), and RapID NH (Remel, Lenexa, KS, USA) strips in accordance with the manufacturer’s instructions.

Six isolates were collected sequentially from the patient over 13 months. We chose to analyze the first (October 2007), middle (May 2008), and final (November 2008) isolates from the patient and compared them with the other B. petrii isolates. The Bordetella reference strain and clinical isolates used in this study are listed in Table 1. Bacterial suspensions were prepared from bacteria grown on Bordet-Gengou agar, supplemented with 15% defibrinated blood (BGA, Difco, Detroit, MI, USA) for 24 h at 36°C, which were then resuspended in saline at 1.8 × 10¹⁰ CFU/mL.

 Sequencing of the 16S rRNA, risA, and ompA Genes

DNA from the selected isolates was extracted by using a DNeasy blood and tissue kit (QIAGEN, Courtaboeuf, France). DNA amplification of the 16S rRNA gene was performed as previously described (29,30). Amplification and sequencing of the genes for the Bordetella outer membrane protein A (ompA) and the response regulator (risA) was performed by using the method described by von Wintzingerode et al. (1) with a few modifications. To optimize PCR amplification conditions, we designed primers for the ompA gene (ompA3e: 5’-CTC CTC CAA

| Table 1. Reference strains and isolates of Bordetella spp. isolates used in this study, October 2007–November 2008 |
|-----------------|----------------|--------------------------------|----------------|
| Isolate         | Species        | Year collected | Origin           | Reference |
| FR3799          | B. petrii      | 2007           | Human            | This study |
| FR3891          | B. petrii      | 2008           | Human            | This study |
| FR 3996         | B. petrii      | 2008           | Human            | This study |
| FR3497          | B. petrii      | 1995           | Human            | (17)       |
| KMBW            | B. petrii      | Unknown        | Environment      | (1)        |
| CIP 8132 (Tolama) | B. pertussis  | 1985           | Human            | (26)       |
| Bpp12822        | B. parapertussis | 1993       | Human            | (26)       |
| Bbs RB50        | B. bronchiseptica | Unknown    | Rabbit           | (27)       |
| Bho1            | B. holmesii    | 2007           | Human            | (28)       |
ATT CGC TCT GGC-3' and ompA4b: 5'-GCA GTT GGC CCT TGC CTT-3') and risA gene (RisA1c: 5'-AAA ACA CCA ATC CCA TCC GC-3' and RisA2d: 5'-ACA GGT TGA GCA CAT AGG GC-3').

The nucleotide sequences of 16S rRNA, risA, and ompA genes from the 3 isolates of the patient (FR3799, FR3891, FR3996) and from the other isolate of human origin (FR3497) have been submitted to the EMBL Nucleotide Sequence Database under the respective accession numbers FN691469/FN691470/FN691471/FN691472; FR669151/FR669152/FR669153/FR669154; and FR669155/FR669156/FR669157/FR669158. For comparative sequence analysis of the 3 different genes, the software, clustalW was used (31).

Matrix-assisted Laser Desorption and Ionization Time-of-Flight (MALDI-TOF) Identification

A MALDI-TOF Axima Assurance (Shimadzu-Biotech Corp., Kyoto, Japan) was used. A positive ion mode, liner mode of detection was running, with a laser frequency of 50 Hz and a mass range window of 2,000–30,000 kDa. The sample was prepared, in duplicate, by a direct deposit of a colony fraction on a target plate, and addition of 50 μL of matrix (acide 4-cyano-4-hydroxycinnamique, AnagnosTec, Potsdam-Golm, Germany), and drying at ambient temperature. Controls and calibration were done with Escherichia coli CCGU 10979 (Culture Collection Göteborg University, Göteborg, Germany). One hundred spectra were obtained, with Launchpad version 2.8 software for spectrum acquisition (Shimadzu-Biotech Corp). Spectra were analyzed with Saramis software, version 3.3.2 (AnagnosTec).

Antimicrobial Drug Susceptibility Testing

MICs were determined by using Etest strips (AB Biodisk, Solna, Sweden; bioMérieux) in accordance with the manufacturer’s recommendations (EAS 004 2007–6), with 0.5 McFarland inoculum on Mueller-Hinton medium, supplemented with 15% horse blood in an atmosphere of 9% CO₂ at 37°C (32,33). Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as controls. We tested the following: penicillin, amoxicillin, piperacillin, piperaclillin and tazobactam, cefotaxime, ceflazidime, ertapenem, imipenem, meropenem, doripenem, gentamicin, tobramycin, amikacin, levofloxacin, ciprofloxacin, moxifloxacin, minocycline, tigecycline, cotrimoxazole, fosfomycin, quinupristin and dalfopristin, rifampin, daptomycin, linezolid, clindamycin, and fucidic acid.

Additional Tests

Pulsed-field gel electrophoresis (PFGE) analysis was performed as described by Caro et al. (34). Western blot analyses were performed as previously described (35). Serum specimens used included polyclonal specific murine serum specimens (anti-FHA, PRN, PT, AC-Hly) (35), the serum collected 7 months after the hospitalization of the patient infected with B. petrii, and 2 pools of serum samples from patients infected with B. pertussis and B. bronchiseptica, respectively.

Fimbrial protein expression was detected by agglutination with monoclonal anti-Fim2 and anti–Fim-3 antibodies. Cytotoxicity of bacteria to murine alveolar macrophage J774-A1 cells was measured as previously described by Bassinet et al. (36).

Results

The bacteria isolated from the patient grew slowly on the chocolate, Haemophilus chocolate, and BCP agar plates. On routine media, the bacteria were irregular gram negative cocobacillus, nonmotile, and strictly aerobic. They tested positive for oxidase and catalase, were susceptible to colistin, and grew at 36°C, 25°C, and 42°C.

Automated routine identification showed twice that this bacterium was in the Moraxella group (probability 95%). API 32GN identified the bacteria at 24 h as Methylobacterium mesophilicum (doubtful identification: 98.4%, with low typicity index [T] = 0.39) and at 48 h as Acinetobacter, Pseudomonas, or Achromobacter (nonreliable identification). API 20NE identified the bacteria (profile code 1001067) with weak discrimination as Achromobacter dentrificicans (31.1%; T = 0.59) or B. bronchiseptica (67.1%; T = 0.66). RapID NH gave Haemophilus influenzae as first choice (inadequate identification; probability 76%; bioscore 1/610).

At 48 h to 72 h, cultures on BGA medium showed small, nonhemolytic colonies ≈1 mm in diameter, which were not producing any brown pigment. These tested negative for urease production. The spectra obtained gave a good identification of B. petrii (identification agreement 55.4%).

The sequencing of the 16S rRNA confirmed the MALDI-TOF identification. The 16S sequences showed 99% of similarity with the 16S rRNA gene sequences from the type strain of environmental origin and the other isolate from human origin. We then performed the sequencing of risA and ompA genes to compare with the genes of the other B. petrii isolates. The risA gene sequences of the clinical isolates showed 93% similarity with the type strain of environmental origin. The species with the next highest similarities were B. bronchiseptica, B. parapapertussis, and B. pertussis, all with a nucleotide identity of 87%. The ompA gene sequences of the clinical isolates demonstrated 89% similarity with the type strain of environmental origin. The species with the next highest similarities were B. bronchiseptica, B. parapapertussis, and B. pertussis, all with a nucleotide identity of 86%. The
weaker score obtained with *ompA* was due to an insertion of 12 nt versus the environmental strain, nucleotides not present in the other isolates from human origin.

The data regarding antimicrobial drug susceptibility obtained are shown in Table 2. Results are compared with other data available from the literature.

As shown in Figure 1, the PFGE patterns obtained with the DNA from the 3 isolates of the reported human case-patient are identical, whereas the patterns obtained with the DNA of the other isolate from human origin and the isolate from the environment show several differences. This indicates that the isolates of the present study are related but part of a different PFGE group.

Results were negative for Fim2 and Fim3 by using the agglutination technique as were results for FHA, PRN, PT, and AC-Hly by Western blot (data not shown) with specific antibodies. As shown in Figure 2, the serum of the patient infected with *B. petrii* recognized several proteins in the bacterial suspensions of the 3 *B. petrii* isolates collected from the patient. The same proteins are recognized in the bacterial suspensions of the 2 other *B. petrii* isolates of clinical and environmental origin, except for 1 low-molecular-weight protein. Most of these proteins, with small differences in molecular weights, are also recognized in bacterial suspensions of *B. pertussis*, *B. parapertussis*, *B. bronchiseptica*, and *B. holmesii*, except for 1 protein.

The pools of serum samples from patients infected with *B. pertussis* and *B. bronchiseptica* recognized high-molecular-weight proteins expressed by *B. pertussis*, *B. parapertussis*, and *B. bronchiseptica* in the bacterial suspensions of these 3 species. However, they did not recognize these high-molecular-weight proteins in the bacterial suspensions of *B. petrii* and *B. holmesii*. Finally, the pool of serum samples from patients infected with *B. bronchiseptica* recognized 1 protein in the *B. pertussis*, *B. parapertussis*, *B. bronchiseptica* and *B. holmesii* bacterial suspensions but not in the *B. petrii* bacterial suspensions.

In terms of cytotoxicity, *B. pertussis* and *B. bronchiseptica* are cytotoxic for the J774-A1 macrophages. However, none of the *B. petrii* isolates were cytotoxic.

**Discussion**

Identification of *B. petrii* is still a major problem for clinical laboratories that use automated or manual identification systems. As suggested by Zbinden et al. (37) isolates that do not give a 99% or better typing result should be typed by 16S rRNA sequencing or MALDI-TOF. The spectra obtained here with MALDI-TOF gave

---

**Table 2. Antimicrobial drug susceptibility testing for Bordetella petrii isolates, by strain and strain type, October 2007–November 2008***

| Drug                   | FR 3799, clinical† | FR 3891, clinical† | FR 3996, clinical† | FR 3497, clinical (17) | KMRW, environmental (1) | Fry et al., clinical (16)‡ | Stark et al., clinical (18) |
|------------------------|--------------------|--------------------|--------------------|-------------------------|-------------------------|---------------------------|---------------------------|
| Penicillin             | >32                | >32                | >32                | >32                     | >32                     | >32                       | ND                        |
| Amoxicillin            | >256               | >256               | >256               | >256                    | >256                    | +clav: 4                  | ND                        |
| Piperacillin           | 16                 | 12                 | 12                 | 256                     | 8                       | ND                        | ND                        |
| Piperacillin and tazobactam | 16             | 48                 | 24                 | 256                     | 0.38                    | 2                        | ≤4                       |
| Cefotaxime             | >32                | >32                | >32                | >32                     | >32                     | >32                       | Ceftriax: >64             |
| Cefazidime             | 48                 | 256                | >256               | 2                       | 4                       | 32                        | 16                       |
| Ertapenem              | >32                | >32                | >32                | 0.016                   | 0.047                   | >32                       | ND                        |
| Imipenem               | 3                  | 8                  | 8                  | 0.75                    | >32                     | >32                       | ND                        |
| Meropenem              | 12                 | >32                | 12                 | 0.023                   | 0.047                   | >32                       | ≤0.25                    |
| Doripenem              | 32                 | >32                | >32                | 0.094                   | 0.125                   | ND                        | ND                       |
| Gentamycin             | 1                  | 1                  | 1.5                | 12                      | 3                       | 4                         | 4                        |
| Tobramycin             | 1                  | 1                  | 1                  | 64                      | 4                       | 16                        | 2                        |
| Amikacin               | 8                  | 16                 | 16                 | 64                      | 48                      | >256                      | 8                        |
| Levofloxacin           | 16                 | 24                 | 24                 | 2                       | 0.25                    | ND                        | ND                       |
| Ciprofloxacin          | >32                | >32                | >32                | 4                       | 0.38                    | >32                       | 2                        |
| Moxifloxacin           | 12                 | 12                 | 12                 | 1.5                     | 0.032                   | ND                        | ND                       |
| Minocycline            | 0.75               | 0.75               | 0.75               | 0.5                     | 0.125                   | ND                        | ND                       |
| Tygucycline            | 0.75               | 1                  | 1                  | 0.25                    | 0.023                   | ND                        | ND                       |
| Cotrimoxazole          | 0.50               | 0.50               | 0.50               | 0.012                   | 0.006                   | 8                         | ND                       |
| Fosfomycin             | 4                  | 8                  | 8                  | 6                       | 12                      | ND                        | ND                       |
| Quinupristin and dalfopristin | >32          | >32                | >32                | >32                     | >32                     | >32                       | ND                       |
| Rifampin               | >32                | >32                | >32                | >32                     | >32                     | >32                       | ND                       |
| Daptomycin             | >256               | >256               | >256               | >256                    | >256                    | >256                      | ND                       |
| Linezolid              | >256               | >256               | >256               | >256                    | >256                    | >256                      | ND                       |
| Clindamycin            | >256               | >256               | >256               | >256                    | >256                    | >256                      | ND                       |
| Fucidic acid           | >256               | >256               | >256               | >256                    | >256                    | >256                      | ND                       |

*Values are MICs by Etest in μg/mL. +clav, in combination with clavulanic acid; Ceftriax, ceftriaxone tested instead of cefotaxime; ND, not determined.
†This study.
‡Ampicillin was tested instead of amoxicillin.
an acceptable identification of *B. petrii* (identification agreement 55.4%). This is a good score, especially because the database contains only 5 spectra of this recently described species because of the low number of isolates available. The phenotypic characteristics of the isolates in our study are similar to those of the few isolates that have been previously described (1,16–19).

In a previous study on *B. bronchiseptica*, we and others working on *Bordetella* spp. (16) determined that the results obtained for many antimicrobial drugs using the disk diffusion method correlated poorly with clinical therapeutic results and with MICs established using the reference method (32,33; A. Le Coustumier, unpub. data). Fry et al. (16) reported that the clinical isolate was apparently susceptible, by disk diffusion tests, to 5 antimicrobial drugs: clarithromycin, erythromycin, gentamicin, ceftriaxone, and piperacillin+tazobactam. However, the respective reference MICs indicated that only piperacillin+tazobactam was active in vitro with a MIC of 2 μg/mL. Based on the preliminary results the patient received a 6-week course of oral clarithromycin treatment. Despite the successful clinical outcome, the isolate was subsequently shown to be resistant to clarithromycin in vitro. In the only other report (to our knowledge) on a clinical *B. petrii* isolate, MICs were determined by using VITEK2 Compact (bioMérieux) but MICs of drugs for *Bordetella* spp. cannot be determined from this database (18). Using Etest strips, a method that has been validated on a wide range of glucose fermenting and nonfermenting gram-negative bacteria, we determined the MIC for 26 widely used antimicrobial drugs from the main therapeutic families (38).

All of the 5 isolates in the present study as well as the isolates described by Fry et al. (16) and Stark et al. (18) appear to have resistance to penicillins (penicillin, amoxicillin), cephalosporins (especially third-generation, extended-spectrum cefotaxime or ceftriaxone and ceftazidime), clindamycin, quinupristin and dalfopristin, rifampin, linezolid, daptomycin, and fucidic acid. We also observed that aminoglycosides had only moderate activity against the bacteria. The isolates in our study also displayed in vitro sensitivity, but low level MICs, to minocyclin, tygecyclin, cotrimoxazole, and fosfomycin.

The large gap in the MICs of amoxicillin and piperacillin between the only environmental isolate available for this study and the clinical isolates may reflect the inducible response to exposure of the clinical isolates to formerly widely used treatment with β-lactams. Tazobactam does not restore the activity of piperacillin, or even degrade it, probably because of the induction of β-lactamase.

In contrast with the isolate of Fry et al. (16) and the environmental isolate (1), the MICs of carbapenems and systemic fluoroquinolones were high for the isolates from our patient. No previous treatment with carbapenems could be documented from the long medical history of our patient, although fluoroquinolones had been frequently prescribed for bronchiectasis. This lack could be partly due to an impermeability-linked cross-resistance between these 2 chemically unrelated families with the common porin mutation, as frequently has been observed for *Pseudomonas aeruginosa*.
Using PFGE, we observed that the patterns of the DNA restriction fragments for the different isolates collected from the reported human patient were quite similar. This finding confirms the persistence of the same isolate inside the host. However, several differences are observed with the patterns of the DNA from the environmental or human isolates. These differences could be linked to the loss of pathogenic islands in some of the isolates, as has been recently reported (22).

Using murine serum samples specific to the major virulence factors expressed by *B. pertussis* and pool of sera from patients infected with either *B. pertussis*, *B. bronchiseptica*, or the serum of the current patient infected with *B. petrii*, we confirmed that *B. petrii* isolates do not express FHA, Fim2 and Fim3, PRN, PT, and AC-Hly. The serum sample from the patient infected with *B. petrii* recognized only 1 protein specific to the *B. petrii* bacterial suspensions derived from the isolates of the clinical patient described in this study. Another protein was specific to the 5 *B. petrii* isolates.

None of the *B. petrii* isolates were cytotoxic for macrophages. This result was likely because these isolates do not express AC-Hly or BteA.

The source of infection and the pathogenic role of *B. petrii* are still unknown. For the study patient, the source of infection, just prior to the first episode, was most likely a contamination that occurred during the aerosol therapy performed at home under poor hygienic conditions (according to the patient). This was potentiated by local corticotherapy.

The prevalence of *Bordetella* spp. within the cystic fibrosis population may well be underestimated, due to the slow growth of this microorganism. However, the prevalence may also be underestimated for all immunosuppressed patients, particularly the elderly. The role that *Bordetellae* spp. such as *bronchiseptica* and *petrii* may play in the progression of pulmonary disease remains unknown, and these species can be misidentified in hospital laboratories (19).

Acknowledgments

We warmly acknowledge Patricia Barré, Michel Fanny, Véronique Kostek, Nathalie and Albine Louchet, Stephane Sire, and Véronique Remy for their kind cooperation in clinical analysis of the case and also the technical staff from the laboratory of clinical microbiology at Cahors Hospital for antibiotic susceptibility testing. We also thank Alain Gravet and Jean-Marie Delarbre for running the MALDI-TOF identification and David Livermore for supplying the Clinical Laboratory and Standards Institute breakpoints data.

This study was supported by the Institut Pasteur Foundation, CNRS URA 3012, and the Institut de Veille Sanitaire.

Dr Le Coustumier is a clinical microbiologist at Centre Hospitalier, Cahors, France. His research interests include human *B. bronchiseptica* infections and the study of nosocomial infections, particularly those caused by methicillin-resistant *Staphylococcus aureus*.

References

1. von Wintzingerode F, Schatte A, Siddiqui RA, Rosick U, Göbel UB, Gross R. *Bordetella petrii* sp. nov., isolated from an anaerobic bioreactor, and emended description of the genus *Bordetella*. Int J Syst Evol Microbiol. 2001;51:1257–65.
2. Ko KS, Peck KR, Oh WS, Lee NY, Lee JH, Song JH. New species of *Bordetella*. *Bordetella holmesii* ansorpii sp. nov., isolated from the purulent exudate of an epidermal cyst. J Clin Microbiol. 2005;43:2516–9. DOI: 10.1128/JCM.43.5.2516-2519.2005
3. Fry NK, Duncan J, Malnick H, Cockcroft PM. The first UK isolate of *‘Bordetella ansorpii’* from an immunocompromised patient. J Med Microbiol. 2007;56:993–5. DOI: 10.1099/jmm.0.47078-0
4. Vandamme P, Heyndricks M, Vancanneyt M, Hoste B, De Vos P, Falsen E, et al. *Bordetella trematum* sp. nov., isolated from wounds and ear infections in humans, and reassessment of *alcaligenes denitrificans* rüger and tan 1983. Int J Syst Bacteriol. 1996;46:849–58. DOI: 10.1099/00207713-46-4-849
5. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to *Bordetella pertussis* and other *Bordetella* subspecies. Clin Microbiol Rev. 2005;18:326–82. DOI: 10.1128/CMR.18.2.326-382.2005
6. Cookson BT, Vandamme P, Carlson LC, Larson AM, Sheffield JV, Kersters K, et al. Bacteremia caused by a novel *Bordetella* species, “*B. hinzi*.” J Clin Microbiol. 1994;32:2569–71.
7. Funke G, Hess T, von Graevenitz A, Vandamme P. Characteristics of *Bordetella hinzi* strains isolated from a cystic fibrosis patient over a 3-year period. J Clin Microbiol. 1996;34:966–9.
8. Harrington AT, Castellanos JA, Ziedalski TM, Claridge JE III, Cookson BT. Isolation of *Bordetella avium* and novel *Bordetella* strain from patients with respiratory disease. Emerg Infect Dis. 2009;15:72–4. DOI: 10.3201/eid1501.081767
9. Vandamme P, Hommez J, Vancanneyt M, Monsieurs M, Hoste B, Cookson B, et al. *Bordetella hinzi* sp. nov., isolated from poultry and humans. Int J Syst Bacteriol. 1995;45:37–45. DOI: 10.1099/00207713-45-1-37
10. Gross R, Keidel K, Schmitt K. Resemblance and divergence: the role that *Bordetella holmesii* sp. nov., isolated from an anaerobic *Bordetella avium* strain, plays in the development of infections, particularly those caused by methicillin-resistant *Staphylococcus aureus*. J Clin Microbiol. 1998;36:2179–84. DOI: 10.1128/JCM.36.8.2179-2184.1998
11. Goodnow RA. Biology of *Bordetella bronchiseptica*. Microbiol Rev. 1980;44:722–38.
12. Gueirard P, Weber C, Le Coustumier A, Guiso N. Human *Bordetella bronchiseptica* infection related to contact with infected animals: persistence of bacteria in host. J Clin Microbiol. 1995;33:2002–6.
13. Yih WK, Silva EA, Ida J, Harrington N, Lett SM, George H. *Bordetella holmesii*–like organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerg Infect Dis. 1999;5:441–3. DOI: 10.3201/eid0503.990317
14. Weyant RS, Hollis DG, Weaver RE, Amin MFM, Steigerwalt AG, O’Connor SP, et al. *Bordetella holmesii* sp. nov., a new gram-negative species associated with septicemia. J Clin Microbiol. 1995;33:1–7.
15. Tang YW, Hopkins MK, Kolbert CP, Hartley PA, Severance PJ, Persing DH. *Bordetella holmesii*–like organisms associated with septicemia, endocarditis, and respiratory failure. Clin Infect Dis. 1998;26:389–92. DOI: 10.1086/516323
Like our podcasts?
Sign up to receive email announcements when a new podcast is available.

www.cdc.gov/ncidod/eid/subscribe.htm